MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Strona główna・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Closed

SectorHealthcare

6.91 2.37

Buy Sell

Overview

Share price change

24h

Current

Min

6.51

Max

6.97

Key metrics
By Trading Economics
Income	3M 12M
Sales	21M 76M
P/E Sector Avg	10.049 56.063
Profit margin	15.633
Employees	179
EBITDA	13M 27M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-21.75% downside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	-46M 312M
Previous open	4.54
Previous close	6.91

News Sentiment

By Acuity

50%

166 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

3.07 / 3.075 Support & Resistance

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2026, 17:11 UTC

Major Market Movers

Major News Events

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2 kwi 2026, 17:10 UTC

Major News Events

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3 kwi 2026, 00:00 UTC

Major News Events

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2 kwi 2026, 23:47 UTC

Market Talk

Major News Events

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2 kwi 2026, 21:01 UTC

Major News Events

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2 kwi 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Starbucks and Boyu Capital Finalize China JV

2 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

2 kwi 2026, 20:41 UTC

Earnings

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 kwi 2026, 20:32 UTC

Market Talk

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2 kwi 2026, 20:30 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 20:09 UTC

Market Talk

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2 kwi 2026, 20:01 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 19:46 UTC

Market Talk

Is Oil the New GameStop? -- Market Talk

2 kwi 2026, 19:35 UTC

Market Talk

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2 kwi 2026, 19:29 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 19:24 UTC

Market Talk

Major News Events

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2 kwi 2026, 19:20 UTC

Market Talk

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2 kwi 2026, 19:01 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2 kwi 2026, 19:00 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: Agreement Reached With American Train Dispatchers Association

2 kwi 2026, 18:24 UTC

Acquisitions, Mergers, Takeovers

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2 kwi 2026, 17:44 UTC

Market Talk

Major News Events

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2 kwi 2026, 17:32 UTC

Major News Events

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2 kwi 2026, 17:26 UTC

Earnings

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 kwi 2026, 17:17 UTC

Market Talk

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2 kwi 2026, 17:09 UTC

Market Talk

Major News Events

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-21.75% downside

12 Months Forecast

Average 5 USD -21.75%

High 5 USD

Low 5 USD

Based on 1 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

166 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.